Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

TBC1D15 Inhibitors

TBC1D15 inhibitors belong to a class of chemical compounds designed to target and modulate the activity of the protein TBC1D15, which stands for Tre-2/Bub2/Cdc16 domain family member 15. TBC1D15 is a member of the Tre-2/Bub2/Cdc16 (TBC) domain-containing protein family, which is characterized by the presence of a conserved TBC domain involved in the regulation of small GTPases. Specifically, TBC1D15 plays a role in cellular processes associated with vesicle trafficking and membrane dynamics. It functions as a GTPase-activating protein (GAP) for Rab7, a small GTPase that controls the late endocytic pathway. TBC1D15's activity in hydrolyzing GTP to GDP on Rab7 is essential for regulating endosome maturation, endosome-lysosome fusion, and lysosomal biogenesis. Inhibitors developed to target TBC1D15 are primarily employed in molecular and cellular biology research to investigate the functional properties and regulatory mechanisms associated with this protein.

The development of TBC1D15 inhibitors typically involves a combination of biochemical, biophysical, and structural approaches aimed at identifying or designing molecules that can selectively interact with TBC1D15 and modulate its GAP activity toward Rab7. By inhibiting TBC1D15, these compounds can potentially disrupt the regulation of Rab7-dependent vesicle trafficking, affecting cellular processes reliant on proper endosome maturation and lysosomal biogenesis. Researchers use TBC1D15 inhibitors to explore the intricate roles played by this protein in cellular functions, attempting to unravel its contributions to membrane dynamics, organelle homeostasis, and potential interactions with other cellular pathways. Furthermore, these inhibitors serve as valuable tools for dissecting the broader network of cellular processes involving TBC domain-containing proteins and their regulatory roles in intracellular vesicle trafficking, contributing to our understanding of fundamental cell biology mechanisms and providing insights into potential avenues for further scientific exploration.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

An mTOR inhibitor that may downregulate protein synthesis pathways, potentially reducing TBC1D15 expression.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

A PI3K inhibitor, which might indirectly affect the mTOR signaling and subsequently decrease TBC1D15 expression.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

As a PI3K inhibitor, it could lead to reduced mTOR activity, possibly impacting TBC1D15 expression.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

A DNA methylation inhibitor that could alter gene expression profiles, including that of TBC1D15.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$90.00
$204.00
13
(1)

A diterpene triepoxide that may inhibit transcriptional activity, potentially decreasing TBC1D15 mRNA levels.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

A JNK inhibitor that might modulate transcription factors and result in altered TBC1D15 expression.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

A p38 MAPK inhibitor that could alter signal transduction pathways, potentially impacting TBC1D15 expression.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

Another MEK inhibitor that might lead to reduced ERK pathway signaling, influencing TBC1D15 expression.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

A kinase inhibitor with potential impact on multiple pathways, which could include the regulation of TBC1D15 expression.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

A receptor tyrosine kinase inhibitor that could indirectly affect signaling pathways regulating TBC1D15.